Genovate Biotechnology Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 115.35 million compared to TWD 118.18 million a year ago. Net income was TWD 7.02 million compared to net loss of TWD 7.53 million a year ago. Basic earnings per share from continuing operations was TWD 0.07 compared to basic loss per share from continuing operations of TWD 0.07 a year ago. Diluted earnings per share from continuing operations was TWD 0.07 compared to diluted loss per share from continuing operations of TWD 0.07 a year ago. Basic earnings per share was TWD 0.07 compared to basic loss per share of TWD 0.07 a year ago. Diluted earnings per share was TWD 0.07 compared to diluted loss per share of TWD 0.07 a year ago.
For the nine months, sales was TWD 323.47 million compared to TWD 322.01 million a year ago. Net income was TWD 0.832 million compared to net loss of TWD 1.78 million a year ago. Basic earnings per share from continuing operations was TWD 0.01 compared to basic loss per share from continuing operations of TWD 0.02 a year ago. Diluted earnings per share from continuing operations was TWD 0.01 compared to diluted loss per share from continuing operations of TWD 0.02 a year ago. Basic earnings per share was TWD 0.01 compared to basic loss per share of TWD 0.02 a year ago. Diluted earnings per share was TWD 0.01 compared to diluted loss per share of TWD 0.02 a year ago.